BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 140 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $164,000 | -78.0% | 34,500 | -90.7% | 0.60% | +51.8% |
| Q1 2020 | $745,000 | +12.2% | 372,700 | +93.6% | 0.40% | +407.7% |
| Q4 2019 | $664,000 | +19.9% | 192,479 | -0.5% | 0.08% | +9.9% |
| Q3 2019 | $554,000 | +77.6% | 193,478 | +134.8% | 0.07% | +222.7% |
| Q2 2019 | $312,000 | -20.4% | 82,400 | +71.0% | 0.02% | +22.2% |
| Q1 2019 | $392,000 | +14.0% | 48,200 | -19.9% | 0.02% | -10.0% |
| Q2 2018 | $344,000 | -33.3% | 60,200 | -66.9% | 0.02% | -58.3% |
| Q2 2016 | $516,000 | -65.6% | 181,800 | -65.7% | 0.05% | -68.4% |
| Q1 2016 | $1,500,000 | +65.9% | 530,100 | +505.1% | 0.15% | +32.2% |
| Q4 2015 | $904,000 | +18.3% | 87,600 | +11.9% | 0.12% | 0.0% |
| Q3 2014 | $764,000 | -46.4% | 78,300 | -30.0% | 0.12% | -45.8% |
| Q2 2014 | $1,425,000 | +154.0% | 111,900 | +110.7% | 0.21% | +143.7% |
| Q1 2014 | $561,000 | – | 53,100 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |